Bioconjug. Chem.
| [0004]
|
Int. J. Oncol.
| [0043]
[0182]
|
Mol. Cancer Ther.
| [0043]
[0182]
|
J. Nat. Prod.
| [0043]
[0182]
|
Bioconj. Chem.
| [0043]
[0182]
|
Toxins
| [0061]
|
Pharm. Pat. Analyst
| [0061]
|
Bioconj. Chem.
| [0066]
[0198]
|
Development of a native nanoelectrospray mass spectrometry method for determination of the drug-to-antibody ratio of antibody-drug conjugates
| [0278]
[0526]
|
Proc. Natl. Acad. Sci. USA
| [0284]
|
Int. J. Cancer
| [0284]
|
Adv. Drug Deliv. Rev.
| [0296]
|
Cancer Immunol. Immunother.
| [0296]
|
Cancer Cell
| [0296]
|
Nat. Rev. Cancer
| [0296]
|
Cuff. Opin. Investig. Drugs
| [0296]
|
Adv. Drug Deliv. Rev.
| [0296]
|
β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update
| [0296]
|
Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates
| [0296]
|
Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue
| [0296]
|
Photoactivatable prodrugs of highly potent duocarmycin analogues for a selective cancer therapy
| [0296]
|
Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT
| [0296]
|
Synthesis and biological evaluation of prodrugs based on the natural antibiotic duocarmycin for use in ADEPT and PMT
| [0296]
|
Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SA
| [0296]
|
Glycosidic prodrugs of highly potent bifunctional duocarmycin derivatives for selective treatment of cancer
| [0296]
|
Synthesis of the first spacer containing prodrug of a duocarmycin analogue and determination of its biological activity
| [0296]
|
Determination of the biological activity and structure activity relationships of drugs based on the highly cytotoxic duocarmycins and CC-1065
| [0296]
|
Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies
| [0296]
|
Synthesis and biological evaluation of a novel pentagastrin-toxin conjugate designed for a targeted prodrug mono-therapy of cancer
| [0296]
|
Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies
| [0296]
|
Synthesis and biological studies of different duocarmycin based glycosidic prodrugs for their use in the antibody-directed enzyme prodrug therapy
| [0296]
|
Asymmetric synthesis and biological evaluation of glycosidic prodrugs for a selective cancer therapy
| [0296]
|
Duocarmycin-based prodrugs for cancer prodrug monotherapy
| [0296]
|
Enantio- and diastereoselective synthesis of duocarmycine-based prodrugs for a selective treatment of cancer by epoxide opening
| [0296]
|
Selective treatment of cancer: synthesis, biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 and the duocarmycins
| [0296]
|
Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy
| [0296]
|
Investigation of reactivity and selectivity of DNA-alkylating duocarmycin analogues by high-resolution mass spectrometry
| [0296]
|
Enzyme and proton-activated prodrugs for a selective cancer therapy
| [0296]
|
Proof of principle in the selective treatment of cancer by antibody-directed enzyme prodrug therapy: the development of a highly potent prodrug
| [0296]
|
Highly selective glycosylated prodrugs of cytostatic CC-1065 analogues for antibody-directed enzyme tumor therapy
| [0296]
|
A strategy for tumor-selective chemotherapy by enzymatic liberation of seco-duocarmycin SA-derivatives from nontoxic prodrugs
| [0296]
|
Stereoselective synthesis of (1-alkoxyalkyl) alpha- and beta-D-glucopyranosiduronates (acetal-glucopyranosiduronates): a new approach to specific cytostatics for the treatment of cancer
| [0296]
|
Proton-mediated liberation of aldophosphamide from a nontoxic prodrug: a strategy for tumor-selective activation of cytocidal drugs
| [0296]
|
Synthesis, biological evaluation, and live cell imaging of novel fluorescent duocarmycin analogs
| [0296]
|
Synthesis of Fluorescence-Labelled Glycosidic Prodrugs Based on the Cytotoxic Antibiotic Duocarmycin
| [0296]
|
International Edition
| [0296]
|
Synthesis and Biological Evaluation of Novel Analogues and Prodrugs of the Cytotoxic Antibiotic CC-1065 for Selective Cancer Therapy
| [0296]
|
Prodrugs of the Cytostatic CC-1065 That Can Be Activated in a Tumor-Selective Manner
| [0296]
|
Amide N-glycosylation by Asm25, an N-glycosyltransferase of ansamitocins
| [0296]
|
A novel amide N-glycoside of ansamitocins from Actinosynnema pretiosum
| [0296]
|
Cancer J
| [0297]
|
Cancer Res.
| [0382]
|
Physicians Desk Reference
| [0529]
|
Synthesis
| [0552]
|
J. Org. Chem.
| [0552]
|
Angew. Chem. Int. Ed.
| [0591]
[0592]
|
Org. Lett.
| [0594]
|
Org. Biomol. Chem.
| [0594]
|
Chemistry & Biology
| [0667]
|
Cancer Res
| [0668]
|
Mol. Cancer Ther.
| [0669]
|
J. Natl. Cancer Inst.
| [0670]
|
Chem. Eur. J.
| [0671]
|